Overview

Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose

Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
To determine whether dose escalation can provide a better survival to patients who failed with icotinib at routine dose.
Phase:
Phase 4
Details
Lead Sponsor:
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co.,Ltd.